Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

Andrew J Yee, Noopur S RajeDivision of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USAAbstract: Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast and prostate cancer. Denosumab is a monoclonal...

Full description

Bibliographic Details
Main Authors: Yee AJ, Raje NS
Format: Article
Language:English
Published: Dove Medical Press 2012-09-01
Series:Clinical Interventions in Aging
Subjects:
denosumab breast cancer prostate cancer bone loss
Online Access:https://www.dovepress.com/denosumab-a-rank-ligand-inhibitor-for-the-management-of-bone-loss-in-c-peer-reviewed-article-CIA

Internet

https://www.dovepress.com/denosumab-a-rank-ligand-inhibitor-for-the-management-of-bone-loss-in-c-peer-reviewed-article-CIA

Similar Items